NCT05442983View on ClinicalTrials.gov

A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

75

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

September 7, 2022

Study Completion Date

October 8, 2022

Conditions

COVID-19

Interventions

DRUG

PanCytoVir™ (probenecid)

Active drug

DRUG

Placebo

Matching placebo

Trial Locations (1)

Unknown

PCMCs PGI Yashwantrao Chavan Memorial Hospital, Pune

All Listed Sponsors

lead

TrippBio, Inc.

INDUSTRY